Are you using tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroendocrine tumors of GI (non-lung) origins?

We have treated a few patients with DLL3+ extrapulmonary NECs (epNECs) with tarlatamab, but we have not reported our experience yet. There have been responses, but mostly short-lived, but I know of cases where the responses were more durable than one would expect in epNECs progressing on first-line ...